Please login to the form below

Not currently logged in
Email:
Password:

Onglyza

This page shows the latest Onglyza news and features for those working in and with pharma, biotech and healthcare.

FDA won't add outcomes data to Januvia label

FDA won't add outcomes data to Januvia label

Those concerns have caused warnings to be imposed on some rival drugs, namely AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin).

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015. ... Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    Qtern combines the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) with SGLT2 inhibitor Farxiga/Forixiga (saxagliptin), and is the second drug of its type on the market after ... Since then however, Onglyza and certain other DPP4

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    Importantly the recommendations put the SGLT2 inhibitors on a par with another newer class of diabetes drug - DPP-4 inhibitors such as MSD's Januvia (sitagliptin) and AstraZeneca's Onglyza (saxagliptin).

  • FDA rejects AZ's diabetes combination FDA rejects AZ's diabetes combination

    The combination of DPP-4 inhibitor saxagliptin - sold by AZ as Onglyza - and SGLT2 inhibitor dapagliflozin (marketed as Farxiga/Forixiga) is considered to be a key component of the company's

  • The role of pharma in the digital world of patient and doctors The role of pharma in the digital world of patient and doctors

    For us, that would be going to a website after being diagnosed with diabetes [AZ markets type II oral medicines Forxiga, Byetta, Bydureon and Onglyza], and make sure that here, we

More from news
Approximately 10 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... As AZ can attest

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics